| Literature DB >> 32653836 |
Soeun Park1, Changik Yoon2, Soong June Bae2, Chihwan Cha2, Dooreh Kim2, Janghee Lee2, Sung Gwe Ahn2, Tai Suk Roh3, Young Seok Kim3, Joon Jeong4.
Abstract
BACKGROUND: Nipple-sparing mastectomy (NSM), followed by immediate reconstruction (IR) of the breast, has become a preferred surgical procedure with good cosmesis results and patient satisfaction. However, nipple-areolar complex (NAC) ischemia and necrosis remain major problems after NSM and IR.Entities:
Keywords: Complication; Incision; Nipple-areolar complex necrosis; Nipple-sparing mastectomy
Mesh:
Year: 2020 PMID: 32653836 PMCID: PMC7375566 DOI: 10.1016/j.breast.2020.06.009
Source DB: PubMed Journal: Breast ISSN: 0960-9776 Impact factor: 4.380
Fig. 1Incisions in nipple-sparing mastectomy (A: periareolar, B: radial, C: inframammary fold).
Demographics of overall cases (n = 290).
| Age, years | 46.5 ± 7.9 |
| BMI, kg/m2 | 22.40 ± 2.95 |
| HTN | 19 (6.6%) |
| DM | 6 (2.1%) |
| Smoking | 5 (1.7%) |
| Neoadjuvant CTx | 34 (11.7%) |
| Pre RTx Hx | 21 (7.2%) |
| Pre surgery Hx | 48 (16.6%) |
| Site | |
| Right | 147 (50.7%) |
| Left | 143 (49.3%) |
| TND, cm | 2.81 ± 1.61 |
| Breast weight, g | 387.22 ± 178.80 |
| Axillary surgery | |
| Not done | 13 (4.5%) |
| SLNB | 208 (71.7%) |
| ALND | 69 (23.8%) |
| Oncologic surgeon | |
| A | 235 (81.0%) |
| B | 52 (17.9%) |
| Others | 3 (1.0%) |
| Plastic surgeon | |
| A | 212 (73.1%) |
| B | 78 (26.9%) |
| Reconstruction | |
| DTI | 258 (89.0%) |
| Tissue expander | 19 (6.6%) |
| Autologous | 13 (4.5%) |
| Postmastectomy RTx | 50 (17.2%) |
Data are mean ± standard deviation or n (%).
Missing value: (BMI: body mass index, HTN, hypertension, DM: diabetes mellitus, CTx: chemotherapy, Pre: previous, RTx: radiation therapy, Hx: history, TND: tumor-nipple distance, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection, DTI: direct-to-implant).
Characteristics according to incision types.
| IMF (n = 176) | Radial (n = 53) | Periareolar (n = 61) | P | |
|---|---|---|---|---|
| Age, years | 47.2 ± 7.3 | 45.8 ± 7.9 | 45.1 ± 9.37 | 0.146 |
| BMI, kg/m2 | 22.4 ± 3.1 | 23.2 ± 2.7 | 21.7 ± 2.7 | 0.037 |
| Smoking | 4 (2.3%) | 0 (0.0%) | 1 (1.6%) | 0.825 |
| DM | 4 (2.3%) | 1 (1.9%) | 1 (1.6%) | >0.999 |
| HTN | 8 (4.5%) | 5 (9.4%) | 6 (9.8%) | 0.181 |
| Pre RTx | 13 (7.4%) | 6 (11.3%) | 2 (3.3%) | 0.261 |
| Neoadj. CTx | 26 (14.8%) | 6 (11.3%) | 2 (3.3%) | 0.054 |
| Pre Surgery Hx | 28 (15.9%) | 11 (20.8%) | 9 (14.8%) | 0.648 |
| TND | 2.78 ± 1.64 | 2.49 ± 1.52 | 3.12 ± 1.59 | 0.126 |
| Axillary surgery | 0.135 | |||
| Not done | 10 (5.7%) | 2 (3.8%) | 1 (1.6%) | |
| SLNB | 123 (69.9%) | 34 (64.2%) | 51 (83.6%) | |
| ALND | 43 (24.4%) | 17 (32.1%) | 9 (14.8%) | |
| Oncologic surgeon | ||||
| A | 133 (75.6%) | 45 (84.9%) | 57 (93.4%) | |
| B | 42 (23.9%) | 7 (13.2%) | 3 (4.9%) | |
| Others | 1 (0.6%) | 1 (1.9%) | 1 (1.6%) | |
| Breast weight | 352.7 ± 160.6 | 438.9 ± 178.0 | 444.7 ± 206.6 | |
| Reconstruction | ||||
| DTI | 164 (93.2%) | 48 (90.6%) | 46 (75.4%) | |
| Tissue expander | 12 (6.8%) | 4 (7.5%) | 3 (4.9%) | |
| Autologous | 0 (0.0%) | 1 (1.9%) | 12 (19.7%) | |
| Implant volume, ml | 210.6 ± 69.9 | 234.1 ± 67.3 | 260.3 ± 76.2 | |
| Postmastectomy RTx | 31 (17.6%) | 13 (24.5%) | 6 (9.8%) | 0.124 |
Data are mean ± standard deviation or n (%).
Fisher’s exact test.
Missing value: (BMI: body mass index, DM: diabetes mellitus, HTN: hypertension, Neoadj.: neoadjuvant, CTx: chemotherapy, Pre: previous, RTx: radiotherapy, Hx: history, TND: tumor-nipple distance, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection, DTI: direct-to-implant).
Complication rate according to incision types.
| Total (%) | IMF (%) | Radial (%) | Periareolar (%) | P | |
|---|---|---|---|---|---|
| 78 (26.9) | 33 (18.8) | 19 (35.8) | 26 (42.6) | ||
| Infection | 13 (4.5) | 4 (2.3) | 4 (7.5) | 5 (8.2) | 0.057 |
| Skin necrosis | 25 (8.6) | 14 (8.0) | 6 (11.3) | 5 (8.2) | 0.801 |
| Nipple necrosis | 45 (15.5) | 17 (9.7) | 9 (17.0) | 19 (31.1) | |
| (Complete necrosis) | 25 (8.6) | 6 (3.4) | 6 (11.3) | 13 (21.3) | |
| Implant removal | 11 (3.8) | 6 (3.4) | 3 (5.7) | 2 (3.3) | 0.625 |
| Other | 15 (5.2) | 7 (4.0) | 4 (7.5) | 4 (6.6) | 0.454 |
| Surgical treatment | 54 (18.6) | 22 (14.1) | 13 (26.0) | 19 (31.7) |
Fisher’s exact test.
Risk factors of nipple-areola complex necrosis: univariable analysis.
| Risk factor | OR | 95% CI | P |
|---|---|---|---|
| Age | 1.012 | 0.972–1.053 | 0.565 |
| BMI | 1.045 | 0.945–1.156 | 0.392 |
| HTN | 1.496 | 0.473–4.733 | 0.493 |
| DM | 1.091 | 0.124–9.564 | 0.937 |
| 0.146 | 0.019–1.096 | ||
| Pre RTx Hx | 0.901 | 0.254–3.194 | 0.871 |
| Pre surgery Hx | 0.744 | 0.296–1.869 | 0.529 |
| Site | |||
| Right | Reference | ||
| Left | 0.980 | 0.519–1.851 | 0.951 |
| 0.814 | 0.647–1.024 | ||
| DTI | Reference | ||
| Tissue-expander | 1.120 | 0.311–4.033 | 0.810 |
| Autologous | 3.733 | 1.158–12.032 | |
| Inframammary | Reference | ||
| Radial | 1.913 | 0.798–4.586 | 0.146 |
| Periareolar | 4.231 | 2.024–8.845 | |
| 1.003 | 1.001–1.004 | ||
| Implant volume | 1.006 | 1.002–1.011 | |
| Initial tissue expander volume | 1.001 | 0.989–1.013 | 0.868 |
Missing value: (OR: odds ratio, CI: confidence interval, BMI: body mass index, HTN, hypertension, DM: diabetes mellitus, Neoadj.: neoadjuvant, CTx: chemotherapy, Pre: previous, RTx: radiotherapy, Hx: history, TND: tumor-nipple distance, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection, DTI: direct-to-implant).
Risk factors of nipple-areola complex necrosis: multivariable analysis.
| Risk factor | Model1 | Model2 | Model3 | |||
|---|---|---|---|---|---|---|
| OR(95% CI) | P | OR(95% CI) | P | OR(95% CI) | P | |
| Periareolar incision (vs. IMF incision) | 4.231(2.024–8.845) | 3.624(1.594–8.239) | 3.628(1.596–8.250) | |||
| TND | 0.777(0.613–0.986) | 0.713(0.547–0.929) | 0.712(0.546–0.927) | |||
| Breast weight | 1.002(1.001–1.004) | 1.002(1.000–1.004) | 1.002(1.000–1.004) | |||
OR: odds ratio, CI: confidence interval, Neoadj.: neoadjuvant, CTx: chemotherapy, TND: tumor-nipple distance.
Model1: Adjusted for year of surgery.
Model2: Adjusted for Neoadj. CTx, oncologic surgeon, TND, reconstruction, incision, breast weight.
Model3: Adjusted for Neoadj. CTx, oncologic surgeon, TND, reconstruction, incision, breast weight, year of surgery.